Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia

  • Yvon Ruch Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France http://orcid.org/0000-0002-4713-9478
  • Charlotte Kaeuffer Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France
  • Aurélien Guffroy Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France
  • Nicolas Lefebvre Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France
  • Yves Hansmann Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France
  • François Danion Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France
DOI: https://doi.org/10.12890/2020_001822

Keywords

COVID-19, coronavirus, cytokine storm syndrome, computed tomography, corticosteroids

Abstract

Background: In June 2020, a large randomised controlled clinical trial in the UK found that dexamethasone was effective in reducing the number of deaths in patients with severe coronavirus disease 2019 (COVID-19).
Case description: We describe a patient with rapid worsening of COVID-19 pneumonia and its dramatic improvement under corticosteroids.
Discussion: Corticosteroids could be useful in patients with an inflammatory profile, considering that acute respiratory distress syndrome may be the consequence of cytokine storm syndrome.

VIEW THE ENTIRE ARTICLE

References

  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–1034.

  • Henderson L, Canna S, Schulert G, Volpi S, Lee P, Kernan K, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheum 2020;72(7):1059–1063.

  • Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani M, et al. Impact of low-dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020;76:31–35.

  • Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568.

  • Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi: 10.1001/jamainternmed.2020.0994 [Epub ahead of print].

  • Oxford University News Release. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. 16 June 2020. Available from: https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf

    • Published: 2020-07-02

    Issue: Vol 7 No 7 (view)

    Section: Articles

    How to cite:
    1.
    Ruch Y, Kaeuffer C, Guffroy A, Lefebvre N, Hansmann Y, Danion F. Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia. EJCRIM 2020;7 doi:10.12890/2020_001822.